| 000 | 01729 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515140747.0 | ||
| 264 | 0 | _c20081107 | |
| 008 | 200811s 0 0 eng d | ||
| 022 | _a1537-453X | ||
| 024 | 7 |
_a10.1097/COC.0b013e318168ef47 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHarshman, Lauren C | |
| 245 | 0 | 0 |
_aThe combination of thalidomide and capecitabine in metastatic renal cell carcinoma -- is not the answer. _h[electronic resource] |
| 260 |
_bAmerican journal of clinical oncology _cOct 2008 |
||
| 300 |
_a417-23 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBone Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aCapecitabine |
| 650 | 0 | 4 |
_aCarcinoma, Renal Cell _xdrug therapy |
| 650 | 0 | 4 |
_aDeoxycytidine _xadministration & dosage |
| 650 | 0 | 4 | _aDisease-Free Survival |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorouracil _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aKidney Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aLiver Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aLung Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aLymphatic Metastasis |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMaximum Tolerated Dose |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNephrectomy |
| 650 | 0 | 4 | _aSurvival Rate |
| 650 | 0 | 4 |
_aThalidomide _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aLi, Mingqing | |
| 700 | 1 | _aSrinivas, Sandy | |
| 773 | 0 |
_tAmerican journal of clinical oncology _gvol. 31 _gno. 5 _gp. 417-23 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/COC.0b013e318168ef47 _zAvailable from publisher's website |
| 999 |
_c18304828 _d18304828 |
||